USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ARTIFICIAL CELL TECHNOLOGIES, INC.
Address:
5 Science Park, 3rd Floor
NEW HAVEN, CT 06511-1989
EIN:
120257077
DUNS:
361522811
Number of Employees:
9
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,642,505.00 4
SBIR Phase II $2,702,977.00 1

Award List:

Polypeptide Multilayer Nanofilms for Synthetic Biomatrix Development

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$331,582.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This SBIR Phase I project will determine the feasibility of applying polypeptide multilayer nanofilm technology to synthetic biomatrix development and commercialization. These nanofilms are a type of surface coating for cell and tissue culture. Immediate in vitro… More

Synthetic nanocapsule malaria vaccines

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this project is to produce novel synthetic malaria vaccines based on epitopes of the circumsporozoite (CS) protein of Plasmodium falciparum, the causative agent of human malaria. Malaria is one of the major diseases in the developing world, causing… More

Synthetic nanoparticle vaccines for RSV

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Thomas J. Powell – 203-772-3430
Abstract:
DESCRIPTION (provided by applicant): Respiratory syncytial virus (RSV) is the most important cause of severe lower respiratory tract illness in infants and the elderly. There is no approved vaccine despite decades of effort. Early attempts to develop a formalin- inactivated vaccine (FI-RSV) resulted… More

Formulation of LbL microparticle vaccine in microneedle array for intradermal del

Award Year / Program / Phase:
2014 / SBIR / Phase I
Award Amount:
$110,923.00
Agency:
HHS
Principal Investigator:
Thomas J. Powell – 203-772-3430
Abstract:
Abstract The ability of the immune system to recognize and initiate an immune response to foreign particles such as bacteria and viruses has generated interest in development of particulate vaccine technologies. We are developing an innovative approach toproduce particulate vaccines via… More

Synthetic microparticle malaria vaccine

Award Year / Program / Phase:
2014 / SBIR / Phase II
Award Amount:
$2,702,977.00
Agency:
HHS
Principal Investigator:
Thomas J. Powell – 203-772-3430
Abstract:
Abstract This Phase II project will develop a novel synthetic microparticle vaccine for malaria, using the T1BT* epitopes of the circumsporozoite (CS) protein of Plasmodium falciparum, the causative agent of human malaria. There is no approved vaccine formalaria, a disease that causes up to 500… More